{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:45:12Z","timestamp":1793335512164,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T00:00:00Z","timestamp":1705017600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s13555-023-01065-0","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T12:02:46Z","timestamp":1705060966000},"page":"187-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Redefining Disease Severity with Special Area Involvement and Reflecting on Treatment Patterns in a Real-World Psoriasis Population"],"prefix":"10.1007","volume":"14","author":[{"given":"Mary E.","family":"Horner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4950-3149","authenticated-orcid":false,"given":"Kate K.","family":"Orroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6249-876X","authenticated-orcid":false,"given":"Junjie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinkang","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1797-0510","authenticated-orcid":false,"given":"Myriam","family":"Cordey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,12]]},"reference":[{"key":"1065_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590","volume":"369","author":"R Parisi","year":"2020","unstructured":"Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369: m1590.","journal-title":"BMJ"},{"key":"1065_CR2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157:940\u20136.","journal-title":"JAMA Dermatol"},{"key":"1065_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70:512\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"1065_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13555-016-0153-2","volume":"7","author":"AW Armstrong","year":"2017","unstructured":"Armstrong AW, Koning JW, Rowse S, Tan H, Mamolo C, Kaur M. Under-treatment of patients with moderate to severe psoriasis in the United States: analysis of medication usage with health plan data. Dermatol Ther (Heidelb). 2017;7:97\u2013109.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1065_CR5","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","volume":"361","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M. Psoriasis. Lancet. 2003;361:1197\u2013204.","journal-title":"Lancet"},{"key":"1065_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, et\u00a0al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82:117\u201322.","journal-title":"J Am Acad Dermatol"},{"key":"1065_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/jdv.18689","volume":"37","author":"U Mrowietz","year":"2023","unstructured":"Mrowietz U, Barker J, Conrad C, Jullien D, Gisondi P, Flower A, et\u00a0al. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas, and impaired quality of life: results from the EMBRACE randomized trial. J Eur Acad Dermatol Venereol. 2023;37:348\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1065_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ced.12805","volume":"41","author":"JF Merola","year":"2016","unstructured":"Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41:486\u20139.","journal-title":"Clin Exp Dermatol"},{"key":"1065_CR9","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3109\/09546634.2012.742176","volume":"25","author":"ML Frez","year":"2014","unstructured":"Frez ML, Asawanonda P, Gunasekara C, Koh C, Loo S, Oon HH, et\u00a0al. Recommendations for a patient-centered approach to the assessment and treatment of scalp psoriasis: a consensus statement from the Asia scalp psoriasis study group. J Dermatolog Treat. 2014;25:38\u201345.","journal-title":"J Dermatolog Treat"},{"key":"1065_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/1346-8138.13841","volume":"44","author":"E Alpsoy","year":"2017","unstructured":"Alpsoy E, Polat M, Fettahl\u0131oGlu-Karaman B, Karadag AS, Kartal-Durmazlar P, YalC\u0131n B, et\u00a0al. Internalized stigma in psoriasis: a multicenter study. J Dermatol. 2017;44:885\u201391.","journal-title":"J Dermatol"},{"key":"1065_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1080\/09546634.2018.1453125","volume":"29","author":"KAP Meeuwis","year":"2018","unstructured":"Meeuwis KAP, Potts Bleakman A, van de Kerkhof PCM, Dutronc Y, Henneges C, Kornberg LJ, et\u00a0al. Prevalence of genital psoriasis in patients with psoriasis. J Dermatolog Treat. 2018;29:754\u201360.","journal-title":"J Dermatolog Treat"},{"key":"1065_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s13555-018-0257-y","volume":"8","author":"KM Beck","year":"2018","unstructured":"Beck KM, Yang EJ, Sanchez IM, Liao W. Treatment of genital psoriasis: a systematic review. Dermatol Ther (Heidelb). 2018;8:509\u201325.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1065_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12589","volume":"31","author":"JF Merola","year":"2018","unstructured":"Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31:e12589.","journal-title":"Dermatol Ther"},{"key":"1065_CR14","volume":"13","author":"AM Alajlan","year":"2021","unstructured":"Alajlan AM, Qadoumi TA. Palmoplantar psoriasis successfully treated with risankizumab. Cureus. 2021;13:e17434.","journal-title":"Cureus"},{"key":"1065_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1159\/000365573","volume":"23","author":"N Al-Mutairi","year":"2014","unstructured":"Al-Mutairi N, Abdalla TO, Nour TM. Resistant palmoplantar lesions in patients of psoriasis: evaluation of the causes and comparison of the frequency of delayed-type hypersensitivity in patients without palm and sole lesions. Med Princ Pract. 2014;23:561\u20137.","journal-title":"Med Princ Pract"},{"issue":"3","key":"1065_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/24755303231160683","volume":"8","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Gondo GC, Bell S, Echeverr\u00eda C, Schmitt-Egenolf M, Skov L, et\u00a0al. Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities. J Psoriasis Psoriatic Arthritis. 2023;8(3):100\u20136.","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"1065_CR17","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1038\/jid.2015.296","volume":"135","author":"J Takeshita","year":"2015","unstructured":"Takeshita J, Gelfand JM, Li P, Pinto L, Yu X, Rao P, et\u00a0al. Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Invest Dermatol. 2015;135:2955\u201363.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"1065_CR18","first-page":"2050","volume":"12","author":"AC Nicolescu","year":"2022","unstructured":"Nicolescu AC, Ionescu MA, Constantin MM, Ancuta I, Ionescu S, Niculet E, et\u00a0al. Psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness. Life (Basel, Switzerland). 2022;12(12):2050.","journal-title":"Life (Basel, Switzerland)."},{"key":"1065_CR19","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","volume":"84","author":"CA Elmets","year":"2021","unstructured":"Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et\u00a0al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84:432\u201370.","journal-title":"J Am Acad Dermatol"},{"key":"1065_CR20","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3899\/jrheum.120237","volume":"89","author":"JM Gelfand","year":"2012","unstructured":"Gelfand JM, Yeung H. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012;89:24\u20138.","journal-title":"J Rheumatol Suppl"},{"key":"1065_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1001\/jamadermatol.2020.5844","volume":"157","author":"E Carr","year":"2021","unstructured":"Carr E, Mahil SK, Brailean A, Dasandi T, Pink AE, Barker JN, et\u00a0al. Association of patient mental health status with the level of agreement between patient and physician ratings of psoriasis severity. JAMA Dermatol. 2021;157:413\u201320.","journal-title":"JAMA Dermatol"},{"key":"1065_CR22","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/jdv.17188","volume":"35","author":"R Sommer","year":"2021","unstructured":"Sommer R, Augustin M, Hilbring C, St\u00e4nder S, Hubo M, Hutt HJ, et\u00a0al. Significance of chronic pruritus for intrapersonal burden and interpersonal experiences of stigmatization and sexuality in patients with psoriasis. J Eur Acad Dermatol Venereol. 2021;35:1553\u201361.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1065_CR23","doi-asserted-by":"publisher","first-page":"e995","DOI":"10.1111\/jdv.18400","volume":"36","author":"N da Silva","year":"2022","unstructured":"da Silva N, Augustin M, Hilbring C, von St\u00fclpnagel CC, Sommer R. Patient-physician (dis)agreement on their reports of body surface area affected by psoriasis and its associations with disease burden. J Eur Acad Dermatol Venereol. 2022;36:e995\u20137.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01065-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-01065-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-01065-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T09:44:04Z","timestamp":1706607844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-01065-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-01065-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mary E. Horner: Consultant for Amgen Inc. Kate K. Orroth: Employee and stockholder of Amgen Inc. Junjie Ma: Employee and stockholder of Amgen Inc. Yinkang Duan: Consultant for Amgen Inc. Myriam Cordey: Employee and stockholder of Amgen Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Institutional Review Board approval to conduct this study was not necessary, as this study used deidentified patient records and did not involve the collection, use, or transmittal of individually identifiable data. This observational study based on secondary data from a health care claims and EHR database does not include any data collected from clinical trial participants (the purview of the Declaration of Helsinki).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}